Based on our review and analysis of all currently available data regarding this potential safety signal, FDA has concluded that treatment with an ARB medication does not increase the risk of cancer.
基于我们的评估和对目前全部可利用的安全性资料的分析,FDA得出的结论是:AR B类药物并不增加患者罹患癌症的风险。
Based on our review and analysis of all currently available data regarding this potential safety signal, FDA has concluded that treatment with an ARB medication does not increase the risk of cancer.
基于我们的评估和对目前全部可利用的安全性资料的分析,FDA得出的结论是:AR B类药物并不增加患者罹患癌症的风险。
应用推荐